756525-98-1

Usage

Uses

Used in Bioconjugation:
Mal-PEG2-COOH is used as a bioconjugation agent for the attachment of biomolecules with thiol groups to other molecules or surfaces. The maleimide group reacts with thiols to form stable covalent bonds, enabling the stable linkage of proteins, peptides, or other thiol-containing biomolecules.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Mal-PEG2-COOH is used as a component in drug delivery systems to improve the solubility, stability, and targeted delivery of therapeutic agents. The PEG spacer and terminal carboxylic acid allow for the attachment of drugs or drug carriers, enhancing the bioavailability and therapeutic efficacy of the drug.
Used in Diagnostic Imaging:
In the field of diagnostic imaging, Mal-PEG2-COOH is used as a contrast agent or a component of imaging probes. The PEG spacer and functional groups enable the attachment of imaging agents or targeting moieties, improving the visibility and specificity of imaging techniques.
Used in Tissue Engineering:
In tissue engineering, Mal-PEG2-COOH is used as a component of hydrogels or scaffolds for tissue regeneration. The PEG spacer and functional groups allow for the attachment of cell adhesion molecules, growth factors, or other bioactive components, promoting cell attachment, proliferation, and tissue regeneration.

Upstream product

• 121215-45-0 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl chloride 
• 791028-27-8 amino-PEG(2u)-acid 
• 55750-62-4 3-maleimidopropionic acid N-hydroxysuccinimide ester 
• 7423-55-4 3-maleimidepropionic acid 
• 756525-95-8 2-methyl-2-propanyl 3-[2-(2-aminoethoxy)ethoxy]propanoate 
• 1629676-61-4 3-(2-(2-(2-(dibenzylamino)ethoxy)ethoxy))tert-butyl propionate 
• 1629676-51-2 C₁₉H₂₅NO₆ 
• 850090-13-0 9-(p-toluenesulfonyloxy)-3,6-diocanonanoic acid tert-butyl ester 
• 133803-81-3 2-methyl-2-propanyl 3-[2-(2-hydroxyethoxy)ethoxy]propanoate 

Downstream Products

• 1037589-69-7 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-{2-[2-(3-oxo-3-{4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]phenylamino}propoxy)ethoxy]ethyl}propanamide 
• 955094-26-5 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-[2-(2-{3-[(2,5-dioxopyrrolidin-1-yl)oxy]-3-oxopropoxy}ethoxy)ethyl]propanamide 

Relevant academic research and scientific papers

Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof

Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

Preparation method of protein cross-linking agent maleimide-dipolyethylene glycol-acrylic acid succinimide ester

The invention relates to the technical field of organic chemical synthesis, and in particular relates to a preparation method of a protein cross-linking agent maleimide-dipolyethylene glycol-acrylic acid succinimide ester. The method comprises the following steps: step 1, synthesizing 3-maleimide propionyl chloride; step 2, synthesizing maleimide-dipolyethylene glycol-acrylic acid; step 3, synthesizing maleimide-dipolyethylene glycol-acryloyl chloride; and step 4, synthesizing the maleimide-dipolyethylene glycol-acrylic acid succinimide ester. An acyl chloride reagent adopted by the method foran esterification reaction is cheaper than a condensation reagent, the costs can be reduced, the purification is convenient, and removal of by-products of the condensation reagent is avoided; and themethod is suitable for industrialized production.

Scalable and cost-effective synthesis of a linker for bioconjugation with a peptide and a monoclonal antibody

An efficient, scalable, and cost-effective synthesis of a linker employed in a bioconjugation process with a peptide and a monoclonal antibody is presented. Several routes were investigated that resulted in the identification of a short synthesis to a key acid intermediate from inexpensive and readily available starting materials. The final coupling of this acid with an aniline to afford the desired linker has been optimized to produce multi-gram quantities of material for clinical studies. The very limited purifications needed for both intermediates and final product make this route amenable to scale. Georg Thieme Verlag Stuttgart New York.

Development of novel linkers to conjugate pharmacophores to a carrier antibody

We have developed modified maleimide novel linkers with improved chemical stability that could potentially be used in conjugating various pharmacophores such as oligo nucleotides, peptides, and proteins to antibodies to afford novel biologics with well-de